Business Context and Reporting Period
This Form 8-K was filed by NanoVibronix, Inc. on August 25, 2017. The report details the entry into a material definitive agreement involving the issuance of debt and equity instruments to an accredited investor. The filing does not contain standard periodic financial statements (e.g., 10-K or 10-Q) for a specific fiscal period.
Key Financial Metrics and Transaction Details
- Debt Issuance: A convertible promissory note with a principal amount of $200,000.
- Interest Rate: 6% per annum, payable in arrears on the Maturity Date.
- Equity Instrument: A seven-year warrant to purchase 80,000 shares of common stock.
- Warrant Exercise Price: $5.90 per share.
- Liquidity Impact: The transaction provides immediate capital of $200,000, subject to the terms of the note.
- Other Metrics: The filing text does not provide clear values for total revenue, net profit, operating cash flow, or existing debt levels outside of this specific transaction.
Material Changes and Terms
The primary material change is the creation of a new direct financial obligation and potential equity dilution. Key terms include:
- Maturity Date: The earlier of the 5-year anniversary of issuance or the date the Company completes a "Qualified Financing" (aggregate proceeds of at least $2,000,000).
- Conversion Mechanics: Upon maturity or a Qualified Financing, the investor may convert the principal and accrued interest into common stock or Series C Convertible Preferred Stock. The conversion price is the lesser of 80% of the Qualified Financing price (or estimated company value per share) or the $5.90 cap.
- Change of Control: In the event of a change of control, the investor may elect cash repayment or conversion at a discounted price based on the implied transaction value.
- Ownership Cap: The warrant holder cannot exercise if it would result in beneficial ownership exceeding 9.99% of outstanding common stock, unless the cap is adjusted with 61 days' notice.
Guidance, Risks, and Contingencies
- Regulatory Status: The issuance was exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D.
- Registration Rights: The warrant may be exercised on a cashless basis if no effective registration statement is available after six months.
- Dilution Risk: The conversion features (80% of price/value) and the warrant exercise price create potential dilution for existing shareholders, particularly if the company's valuation or financing price is low.
- Management Commentary: The filing contains no forward-looking guidance, outlook, or management commentary regarding future operations or financial performance.
Investor Verification Checklist
- Verify the identity of the accredited investor and any related party relationships.
- Review the full text of the Note (Exhibit 10.1) and Warrant (Exhibit 10.2) for specific covenants not summarized here.
- Assess the company's current cash position to determine if the $200,000 infusion is critical for near-term operations.
- Monitor for a "Qualified Financing" (>$2M) which would trigger the note's maturity and conversion.
- Check subsequent filings for any changes in the company's valuation or capital structure that would affect the conversion price.